Anthropic launches Claude Science for drug discovery

The headline everyone reached for was the product, but the consequential move is the business model. Anthropic did not just ship a workbench for scientists - it announced it will run its own preclinical drug discovery programs, becoming the first leading foundation model lab to chase its own drug candidates rather than only renting compute and models to pharma ^[1]. That is vertical integration into an industry Anthropic has never operated in, and it inverts the usual AI-for-science pitch: instead of selling shovels, the company is going down into the mine.

The target choice is telling. Anthropic is aiming at neglected and rare diseases, conditions where, as the company frames it, the underlying biology is often well understood but the economics of traditional drug development are unattractive ^[1]. Its legal structure makes this possible: as a public benefit corporation, Anthropic has room to pursue therapeutic areas that a return-maximizing pharma company would abandon ^[1]. The subtext is a feedback loop - the company argues it needs hands-on drug-development experience to build better AI tools, and those tools in turn attract paying biopharma customers at scale ^[1]. The Verge distilled the strategic shift to its bluntest form: Anthropic wants to develop its own drugs, and that ambition, more than any feature, is what the launch is really about.

Mechanically, Claude Science is a multi-agent system rather than a single chat model. A generalist coordinating agent receives a plain-language request and spins up specialist sub-agents to handle the work, while a separate reviewer agent audits citations and calculations and self-corrects errors before results reach the scientist ^[2]. The design goal is reproducibility: every output carries an auditable history of how it was made, so results can be validated and reproduced, with connections into databases like UniProt, PDB, Ensembl, Reactome, ClinVar, ChEMBL, and GEO ^[3].

The workbench does not pretend a laptop is enough for real biology. It can run locally on macOS or Linux, reach remote machines over SSH, or sit on HPC login nodes, scaling compute from a single GPU to hundreds via Modal or a lab's own infrastructure so datasets never leave existing systems ^[3]. It ships pre-wired with 60+ scientific skills and connectors and folds in NVIDIA BioNeMo models Evo 2, Boltz-2, and OpenFold3 ^[2]. At the launch event, Anthropic demonstrated the system autonomously identifying drug candidates for phenylketonuria - a rare metabolic disorder - as a live proof that the coordinator-plus-reviewer loop can carry a discovery task end to end ^[4]. On X, one widely-shared analyst framing captured the ambition and the catch in a single line: Claude Science is meant to do for lab research what Claude Code did for programming, but drug discovery is messier, because molecules fail when biology, chemistry, safety, or dosing breaks.

For all the star power, the track record it is joining is unglamorous. Coverage of the livestream pointed out the load-bearing fact of the entire AI-drug field: despite years of hype, no AI-designed drug has to date won FDA approval ^[5]. That gap between capability demos and shipped medicine is where practitioners planted their skepticism. Researchers warn the system can hallucinate false-but-convincing data or miss nuance in regulatory guidance, which is precisely why Anthropic built the reviewer agent as a mitigation and why one Northeastern researcher insists on treating it as a co-pilot that requires a skilled pilot ^[6].

The practitioner community split cleanly along this line. On Reddit's bioinformatics and Claude communities, developers praised the literature-discovery layer - one biomedical engineer described it as roughly one-to-one with a manual review - while others read the whole thing as Claude Code with pre-built science tooling that adds little for teams who already wrote their own connectors. A sharper critique surfaced too: that this is open source consumed and then sold back to the people who built it. A Reddit user in biotech R&D reported that a workflow which once took three people two weeks now ran in under an hour via sub-agents, but the same threads flagged that the tool burns through usage limits fast, plots poorly until seeded with an example, and offers little to non-biology fields like plasma physics or computational chemistry. On YouTube, hands-on reviewers echoed the demo enthusiasm while warning of overconfidence in the graphs and visuals it generates - the exact failure mode a regulator, who cares about precision and recall, would punish.

The talent and governance moves around the launch are not decoration - they are the strategy made concrete. Hiring John Jumper, the Nobel laureate who architected AlphaFold, reads as a direct competitive strike: DeepMind dominated AI-for-science for a decade, and Anthropic is now extending its recent lead in coding into science, with the Jumper hire as the signal flare ^[4]. On the board, Novartis CEO Vas Narasimhan brings pharma-scale credibility and a risk-governance template; he has overseen the approval of more than 35 novel medicines ^[9]and argues AI could compress drug-development timelines from 12 years to 7 or 8 and roughly double success rates ^[7].

Underneath sits a revenue story. MIT Technology Review's read is that pharmaceutical partnerships could support Anthropic's profitability as it approaches an IPO ^[4]. Stack that against the roughly $400 million Coefficient Bio acquisition - a sub-10-person stealth biotech absorbed to supply the drug-design engine ^[8]- and the shape becomes clear: buy the science team, hire the field's most credible name, seat a pharma CEO to manage dual-use biosecurity risk, and use in-house neglected-disease programs both to sharpen the product and to signal mission before a market debut. It is a bet that the feedback loop between doing the science and selling the tooling pays off faster than the field's total absence of FDA-approved AI drugs suggests it will.